Table 1.

Cell potency of compounds against genotype 1b wild-type (Con1) and DCV + ASV-resistant replicons and C_trough concentration observed in clinical settings

Agent	EC50 (±SD), nM*			Ctrough, nM*
	GT 1b (Con1) replicon	GT 1b NS3-D168V, NS5A-L31M-Y93H	Fold change
Asunaprevir	2.0 ± 0.4	401 ± 102	201	40†
Daclatasvir	0.002 ± 0.001	49 ± 9	24,500	250†
Beclabuvir	3.4 ± 0.2	4.0 ± 0.7	1	500†
Ledipasvir	0.002 ± 0.0004	131 ± 40	65,500	120 [20]
Sofosbuvir	147 ± 27	102 ± 12	1	1,100†
Simeprevir	1.9 ± 0.1	6,296 ± 203	3,313	2,200†
Next-gen NS5A (BMS-1)	0.010 ± 0.002	0.354 ± 0.05	39	–
Next-gen NS3 PI (BMS-2)	0.7 ± 0.1	4.1 ± 0.6	6	100‡
Ribavirin*	8.1 ± 1.2	7.8 ± 5.7	1	2.5 [21]
Peginterferon alfa*	1.2 ± 0.2	2.6 ± 0.6	2	15 [22]

C _trough trough plasma concentrations, EC ₅₀ 50% effective concentrations, GT genotype, NS3 non-structural protein 3, NS5A non-structural protein 5A, PI protease inhibitor, SD standard deviation

* All EC₅₀ and C_trough concentrations are nM, except for ribavirin (µg/mL) and peginterferon alfa (ng/mL)

^† BMS data on file

^‡ Estimated value